Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging in Primary Brain Tumor Patients Receiving Brain Radiotherapy

What this Trial Is About

Researchers are studying primary brain tumor patients who are undergoing fractionated radiation therapy to the brain. The study aims to understand how radiation affects brain tissue and cognitive function over time by using advanced neuroimaging and neurocognitive testing. The goal is to improve brain radiotherapy techniques to protect cognitive abilities by identifying vulnerable brain regions. Participants will undergo volumetric and diffusion magnetic resonance imaging (MRI) scans and complete neurocognitive tests at several times: before treatment, and at 3, 6, and 12 months after radiation therapy. Clinical information such as age, gender, tumor characteristics, and use of medications like steroids or chemotherapy will be recorded to support the analysis. During the study, participants will be monitored with brain MRI and cognitive assessments to track changes in brain structure and function. Researchers will measure imaging biomarkers such as brain volume and tissue integrity, along with memory, executive function, attention, language, fine motor skills, and quality of life. The total observation period includes assessments up to 12 months post-treatment, with some long-term quality of life evaluations extending to 5 years after therapy.

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients